Celeste Leigh Pearce

List of Publications by Citations

128 papers	7,866 citations	40 h-index	87 g-index
139 ext. papers	9,085 ext. citations	8.2 avg, IF	4.95 L-index

#	Paper	IF	Citations
128	Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nature Genetics*, **2003**, 33, 177-82	36.3	1621
127	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
126	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
125	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nature Genetics*, **2010**, 42, 874-9	36.3	277
124	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
123	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nature Genetics*, **2009**, 41, 996-1000	36.3	240
122	Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. *Human Heredity*, **2003**, 55, 179-90	1.1	230
121	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
120	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
119	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
118	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. *Nature Reviews Cancer*, **2017**, 17, 65-74	31.3	168
117	Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the National Cancer Institute*, **2014**, 106, djt431	9.7	149
116	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, **2013**, 20, 251-62	5.7	135
115	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
114	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *International Journal of Epidemiology*, **2013**, 42, 579-89	7.8	122
113	Prevention of cancers of the breast, endometrium and ovary. *Oncogene*, **2004**, 23, 6379-91	9.2	115
112	Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. *Fertility and Sterility*, **2004**, 82, 186-95	4.8	107

111	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
110	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
109	Markers of inflammation and risk of ovarian cancer in Los Angeles County. *International Journal of Cancer*, **2009**, 124, 1409-15	7.5	84
108	Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. *Cancer*, **2009**, 115, 531-9	6.4	83
107	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630	7.8	77
106	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes and Control*, **2013**, 24, 989-1004	2.8	69
105	Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 671-676	4	67
104	Association Between Life Purpose and Mortality Among US Adults Older Than 50 Years. *JAMA Network Open*, **2019**, 2, e194270	10.4	66
103	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
102	Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. *American Journal of Human Genetics*, **2005**, 76, 82-90	11	65
101	Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prevention Research*, **2013**, 6, 811-21	3.2	64
100	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 245-50	4	64
99	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
98	Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. *Journal of the National Cancer Institute*, **2005**, 97, 51-9	9.7	51
97	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. *International Journal of Cancer*, **2009**, 125, 2214-8	7.5	50
96	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48
95	Determination of sequence variation and haplotype structure for the gonadotropin-releasing hormone (GnRH) and GnRH receptor genes: investigation of role in pubertal timing. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1091-9	5.6	47
94	Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. *PLoS ONE*, **2011**, 6, e28141	3.7	45

93	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
92	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
91	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. *American Journal of Epidemiology*, **2017**, 185, 8-20	3.8	44
90	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, **2010**, 6, e1001016	6	42
89	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
88	The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. *American Journal of Obstetrics and Gynecology*, **2017**, 216, 270.e1-270.e9	6.4	39
87	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 880-90	4	37
86	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. *Human Molecular Genetics*, **2009**, 18, 2297-304	5.6	37
85	Risk of ovarian cancer and the NF-Ƀ pathway: genetic association with IL1A and TNFSF10. *Cancer Research*, **2014**, 74, 852-61	10.1	36
84	Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. *Breast Cancer Research and Treatment*, **2009**, 118, 161-8	4.4	33
83	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
82	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
81	African Americans and Hispanics Remain at Lower Risk of Ovarian Cancer Than Non-Hispanic Whites after Considering Nongenetic Risk Factors and Oophorectomy Rates. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1094-100	4	30
80	The effects of common genetic variants in oncogenes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 5833-9	12.9	30
79	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2016**, 115, 95-101	8.7	28
78	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
77	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1114-24	4	27
76	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26

75	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 395-404	4	25
74	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
73	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
72	Association Between Breastfeeding and Ovarian Cancer Risk. *JAMA Oncology*, **2020**, 6, e200421	13.4	24
71	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstetrics and Gynecology*, **2016**, 127, 828-836	4.9	24
70	Ovarian cancer: density equalizing mapping of the global research architecture. *International Journal of Health Geographics*, **2017**, 16, 3	3.5	23
69	BRCA1 variants in a family study of African-American and Latina women. *Human Genetics*, **2005**, 116, 497-506	6.3	23
68	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1822-30	4	22
67	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
66	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
65	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Human Genetics*, **2014**, 133, 481-97	6.3	21
64	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
63	Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, **2014**, 2, 332-40	12.5	20
62	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 987-92	4	20
61	Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 600-4	4	20
60	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e20703	3.7	20
59	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
58	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18

57	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18
56	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertility and Sterility*, **2011**, 95, 40-5	4.8	18
55	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. *Human Molecular Genetics*, **2011**, 20, 2263-72	5.6	18
54	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
53	Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer*, **2019**, 19, 339-348	31.3	17
52	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
51	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. *Gynecologic Oncology*, **2019**, 153, 343-355	4.9	16
50	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. *International Journal of Epidemiology*, **2018**, 47, 460-472	7.8	16
49	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
48	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
47	Timing of births and oral contraceptive use influences ovarian cancer risk. *International Journal of Cancer*, **2017**, 141, 2392-2399	7.5	14
46	Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	13
45	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2019**, 48, 822-830	7.8	13
44	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. *Molecular Cancer Therapeutics*, **2015**, 14, 1495-503	6.1	13
43	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
42	"I am not a statistic" ovarian cancer survivorsSviews of factors that influenced their long-term survival. *Gynecologic Oncology*, **2019**, 155, 461-467	4.9	12
41	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
40	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11

39	Variation in NF-B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1421-7	4	11
38	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
37	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. *International Journal of Cancer*, **2019**, 144, 2192-2205	7.5	11
36	Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 996-999	4	10
35	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
34	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 174-182	4	10
33	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2019**, 30, 537-547	2.8	9
32	Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. *Cancer Science*, **2018**, 109, 435-445	6.9	9
31	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
30	Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. *Breast Cancer Research and Treatment*, **2012**, 132, 653-60	4.4	9
29	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
28	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
27	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
26	Identification of novel epithelial ovarian cancer loci in women of African ancestry. *International Journal of Cancer*, **2020**, 146, 2987-2998	7.5	8
25	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
24	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
23	A targeted genetic association study of epithelial ovarian cancer susceptibility. *Oncotarget*, **2016**, 7, 7381-9	3.3	7
22	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *International Journal of Cancer*, **2016**, 139, 2646-2654	7.5	6

21	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
20	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 116-125	4	5
19	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
18	Phenotype risk scores (PheRS) for pancreatic cancer using time-stamped electronic health record data: Discovery and validation in two large biobanks. *Journal of Biomedical Informatics*, **2021**, 113, 103652	10.2	5
17	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
16	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
15	Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. *International Journal of Cancer*, **2018**, 142, 460-469	7.5	3
14	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
13	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
12	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. *Epidemiology*, **2020**, 31, 402-408	3.1	3
11	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. *Journal of the National Cancer Institute*, **2021**, 113, 301-308	9.7	3
10	Acupressure for Cancer-fatigue in Ovarian Cancer Survivor (AcuOva) Study: A community-based clinical trial study protocol examining the impact of self-acupressure on persistent cancer-related fatigue in ovarian cancer survivors. *Contemporary Clinical Trials*, **2021**, 107, 106477	2.3	3
9	Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women. *AIDS Research and Human Retroviruses*, **2013**, 29, 755-60	1.6	2
8	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
7	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. *European Journal of Epidemiology*, **2020**, 35, 1025-1042	12.1	2
6	The Association of Prenatal Vitamins and Folic Acid Supplement Intake with Odds of Autism Spectrum Disorder in a High-Risk Sibling Cohort, the Early Autism Risk Longitudinal Investigation (EARLI). *Journal of Autism and Developmental Disorders*, **2021**, 1	4.6	2
5	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 927-935	4	2
4	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.. *JAMA Network Open*, **2022**, 5, e2147343	10.4	1

3	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk	1
2	Endometriosis and ovarian cancer AuthorsSreply. *Lancet Oncology, The*, **2012**, 13, e190	21.7
1	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1028-31	4